BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical …
Full BGLC analysis →
Competitive advantage assessment
Key strengths
Strong Liquidity BufferLiquidity position is strong (score 0.94), providing operational cushion.
Key risks
Commodity Pressure / Weak DifferentiationGross margin at 21.8th percentile with high volatility suggests weak pricing power or commoditized products.
ROIC Below WACC or PeersROIC at 7.3th percentile suggests inefficient capital deployment.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
BioNexus Gene Lab Corp ranks #52 of 56
scored companies in Specialty Chemicals by moat score — the top 93%.
The widest moat in the group is WD-40 Company (WDFC)
at 81/100.
Moat scores for companies ranked near BGLC in Specialty Chemicals
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 12
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 30
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 12
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 36
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 14
· 15% of the moat score
Scale matters only when it converts into economics.
BioNexus Gene Lab Corp (BGLC) scores 19 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #52 of 56 scored companies in Specialty Chemicals, the top 93%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 56 companies in Specialty Chemicals. Its strongest defense is Resilience (36/100) and its weakest is Cost Advantage (12/100).
How does BioNexus Gene Lab Corp compare with other Specialty Chemicals companies?
BioNexus Gene Lab Corp ranks #52 of 56 scored companies in Specialty Chemicals by moat score. The widest moat in Specialty Chemicals is WD-40 Company (WDFC) at 81/100. The companies ranked closest are Lightwave Logic, Inc. (LWLG) at 22 just above it and 5E Advanced Materials, Inc. (FEAM) at 17 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 56 companies in Specialty Chemicals. The defenses are then weighted to produce the overall score out of 100.
Why is BioNexus Gene Lab Corp scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for BioNexus Gene Lab Corp?
The Corporate Default template measures 6 defenses, and BGLC scores: Pricing Power (13), Cost Advantage (12), Customer Stickiness (30), Capital Efficiency (12), Resilience (36), Scale & Market Position (14). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.